MHB046C

PreclinicalSmall molecule

MMinghui Pharmaceutical (Hangzhou) Ltd

MHB046C is one of 44 small molecule programs targeting Advanced Solid Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid CancerRecruiting

Patients With Advanced Solid TumorsRecruiting

Advanced Solid CancerPreclinical

Recruiting

Patients With Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

19 2

Eloxatin

Teva

Phase 2

9 3

Tecentriq

Roche

Phase 2

4 4

Camptosar

Pfizer

Phase 2

4 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 6

Lazcluze

Johnson & Johnson

Phase 2

1 7

Erbitux

IImclone

Phase 2

9 8

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

6 10

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalRecruiting

Advanced Solid Cancer

NCT06985355

Clinical

Trials by Indication[1]

Advanced Solid Cancer1 trial

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB046C Injection in Patients With Advanced Solid Tumors

Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Preclinical·NCT06985355·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MHB046C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MHB046C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MHB046C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minghui Pharmaceutical (Hangzhou) Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinghui Pharmaceutical (Hangzhou) Ltd

MHB046C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Advanced Solid Cancer1 trial

References

Drug Info

Quick Facts

Related News